COMPANY

Titan Pharmaceuticals

HQ: New York, NY source · titanpharm.com ↗ · West Coast

Keywords: opioid use disorder Opioid Dependence Opioid Dependency Parkinson Disease Congestive Heart Failure Prostatic Neoplasms Multiple Myeloma Bladder Neoplasms Lymphoma Malignant Melanoma Leukemia, Lymphocytic, Chronic Small Lymphocytic Lymphoma Non-Small-Cell Lung Carcinoma Pivanex Probuphine DITPA (3,5-diiodothyropropionic acid) Gallium maltolate

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

$1.6MRaised (2 yrs)13Trials (company is sponsor)

Raises and deals from press releases

Raise Private placement · $600K · announced Jun 27, 2025 Company release ↗
Source quote
- Jun 27, 2025 · Company release ↗
  “Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock”
Raise Private placement · $1M · announced Apr 11, 2025 Company release ↗
Source quote
- Apr 11, 2025 · Company release ↗
  “Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock”

Raises announced in these releases: $1.6M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jun 27, 2025 Raise Private placement: $600,000 (total, as published), announced Jun 27, 2025. Source: SEC filing. source ↗
Jun 27, 2025 Raise Private placement · $600K source ↗
Apr 11, 2025 Raise Private placement: $1M (total, as published), announced Apr 11, 2025. Source: SEC filing. source ↗
Apr 11, 2025 Raise Private placement · $1M source ↗
Oct 10, 2017 Trial start Phase 1/Phase 2: Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole source ↗
2014-07 Trial start Phase 3: A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants source ↗
2010-11 Trial start Phase 3: Re-Treatment Study of Probuphine in Opioid Addiction source ↗
2010-04 Trial start Phase 3: A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction source ↗
2008-09 Trial start Phase 3: Study of Probuphine in Patients With Opioid Dependence source ↗
2008-09 Trial start Phase 3: A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence source ↗
2007-10 Trial start Phase 3: Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence source ↗
2006-10 Trial start Phase 3: Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence source ↗
2004-12 Trial start Phase 2: Study of DITPA in Patients With Congestive Heart Failure source ↗
2004-05 Trial start Phase 2: A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia source ↗
2004-01 Trial start Phase 1/Phase 2: A Pilot Study of Pivanex in Patients With Malignant Melanoma source ↗
2003-09 Trial start Phase 2: Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer source ↗
2001-06 Trial start Phase 1/Phase 2: Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies source ↗

Funding

Raised: $1.6M. Last 2 years.

Jun 27, 2025 Private placement: $600,000 (total, as published), announced Jun 27, 2025. Source: SEC filing. source ↗
Apr 11, 2025 Private placement: $1M (total, as published), announced Apr 11, 2025. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 13

Record	Title	Phase	Status	Start	Primary completion
NCT03250117	Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole	Phase 1/Phase 2	Terminated	Oct 10, 2017	May 22, 2018 (actual)
NCT02180659	A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants	Phase 3	Completed	2014-07	2015-05 (actual)
NCT00772785	Study of Probuphine in Patients With Opioid Dependence	Phase 3	Terminated	2008-09	2009-02 (actual)
NCT01262261	Re-Treatment Study of Probuphine in Opioid Addiction	Phase 3	Completed	2010-11	2011-11 (actual)
NCT01114308	A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction	Phase 3	Completed	2010-04	2011-05 (actual)
NCT00768482	A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence	Phase 3	Terminated	2008-09	2008-12 (actual)
NCT00630201	Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence	Phase 3	Completed	2007-10	2009-02 (actual)
NCT00447564	Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence	Phase 3	Completed	2006-10	2008-07 (actual)
NCT00103519	Study of DITPA in Patients With Congestive Heart Failure	Phase 2	Terminated	2004-12	2006-12 (actual)
NCT00050687	Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies	Phase 1/Phase 2	Terminated	2001-06	2005-03 (actual)
NCT00087477	A Pilot Study of Pivanex in Patients With Malignant Melanoma	Phase 1/Phase 2	Terminated	2004-01	Not listed
NCT00083473	A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia	Phase 2	Terminated	2004-05	Not listed
NCT00073385	Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer	Phase 2	Completed	2003-09	Not listed